DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20170153

A study of bone mineral density among people living with HIV in India and its correlation with CD4 count

Kamal K. Sawlani, Sushrut Singh, Shyam C. Chaudhary, D. Himanshu Reddy, Kauser Usman, Virendera Atam

Abstract


Background: Data on the prevalence of osteoporosis in HIV patients in Asian population is scarce this study was done to find out the prevalence of osteoporosis in HIV infected patients and its correlation with CD4 counts.

Methods: This cross- sectional study was conducted in NACO- ART center of tertiary care hospital. Total 115 HIV patients were included in this study which were divided into ART naive (n= 69) and patients taking ART (n= 46). We analysed BMD by DEXA in 115 HIV positive patients and 78 HIV negative age and sex matched controls. Correlation of BMD with a CD4 count and ART regimen was studied.

Results: BMD was found to be low in HIV positive patients. T score in HIV positive patients was significantly lower (p<0.05) as compared to the HIV negative control group. The prevalence of osteopenia and osteoporosis in HIV positive patients was 50.4% and 29.6% respectively, as compared to 23.1% and 2.6% in HIV negative controls. BMD showed relation with CD4 count. We did not find any statistical difference between any ART regimen and BMD.

Conclusions: The prevalence of osteopenia and osteoporosis in HIV infected cases was higher as compared to HIV negative controls and higher in ART group as compared to ART naïve group. Low BMD levels show correlation with low CD4 count. We recommend that HIV positive patients especially with advanced stage of disease, low CD4 count should be screened for low BMD by DEXA scan for osteoporosis and managed accordingly

Keywords


ART, CD4 counts, DEXA, HIV, Osteoporosis

Full Text:

PDF

References


NACO and National Institute of Stastics. India HIV Estimates 2015, Technical Report. Ministry of Health and Family Welfare. Government of India. 2015.

Prior J, Burdge D, Maan E, Milner R, Hankins C, Klein M, et al. Fragility fractures and bone mineral density in HIV positive women: A case-control population-based study. Osteoporos Int. 2007;18:1345-53.

WHO Scientific Group on the Prevention and Management of Osteoporosis. World Health Organization. Geneva. 2003.

Aukrust P, Haug C, Ueland T, Lien E, Muller F, Espevik T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus Infection: indication of normalization of the bone remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab. 1999;84:145-50.

Bischof MG, Heinze G, Vierhapper H. Vitamin D status and its relation to age and body mass index. Horm Res. 2006;66:211-5.

Fessel WJ, Chau Q, Leong D. Association of osteonecrosis and osteoporosis in HIV-1 infected patients. AIDS. 2011;25:1877-80.

Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviralnaive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.

Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14:F63-7.

Tebas P, Umbleja T, Dube M. Initiation of ART is associated with bone loss independent of the specific ART regimen: results of ACTG A5005s. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles, CA). Alexandria, VA: CROI. 2007.

Cotter EJ, Malizia AP, Chew N, Powderly WG, Doran PP. HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Res Hum Retroviruses. 2007;23:1521-30.

Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem. 2003;278:48251-8.

Fakruddin JM, Laurence J. HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol. 2005;150:67-78.

Cotter EJ, Malizia AP, Chew N, Powderly WG, Doran PP. HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Res Hum Retroviruses. 2007;23:1521-30.

Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000;106:1481-8.

Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (Oxford). 2008;47:1635-40.

Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol. 1990;145:3297-303.

Gibellini D, Borderi M, De Crignis E, Cicola R, Vescini F, Caudarella R et al. RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naïve HIV-1-positive men. J Med Virol. 2007;79:1446-54.

Bruera D, Luna N, David DO, Bergoglio M, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 2003;17:1917-23.

Casado JL, Bañon S, Andrés R, Perez-Elías MJ, Moreno A, Moreno S. Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients. Osteoporos Int. 2014;25:1071-9.

Paul TV, Asha HS, Thomas N, Seshadri MS, RupalI P, Abraham OC, et al. Hypovitaminosis D and bone mineral density in human immunodeficiency virus-infected men from India, with or without antiretroviral therapy. Endocri Pract. 2010;16:547.

Knobel H, Guelar A, Vallecillo G, Nogues X, Diez A. Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS. 2001;15:807-8.

Grant PM, Kitch D, McComsey GA, Dube MP, Haubrich R, Huang J, et al. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis. 2013;57:1483-8.

Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, EllisPegler RB, et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab. 2007;92:1283-8.